The AASK trial is designed to evaluate the effectiveness of three anti-hypertensive drug regimens and two levels of blood pressure control on the progression of hypertensive kidney disease.
RCT
Randomized
Sí
Do specific anti-hypertensive drug regimens (ramipril, amlodipine, metoprolol) and lower blood pressure goals improve the rate of change in renal function in African-Americans with hypertensive kidney disease?
The AASK trial is designed to evaluate the optimal anti-hypertensive regimen and blood pressure target for slowing the progression of hypertensive kidney disease in African-Americans.
The African American Study of Kidney Disease and Hypertension (AASK) is a multicenter randomized clinical trial designed to test the effectiveness of three anti-hypertensive drug regimens and two levels of BP control on the progression of hypertensive kidney disease. Participants include African-American men and women aged 18 to 70 yr who have hypertensive kidney disease and GFR between 20 and 65 ml/min per 1.73 m(2). The three anti-hypertensive drug regimens include an angiotensin converting enzyme inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine) or a beta-blocker (metoprolol) as initial therapy. The BP control levels are a lower goal (mean arterial pressure, </=92 mmHg) and a usual goal (mean arterial pressure, 102 to 107 mmHg inclusive). The primary outcome is rate of change in renal function as measured by GFR, assessed by (125) I-iothalamate clearance. The main secondary patient outcome is a composite including the following events: (1) reduction in GFR by 50%, (2) end-stage renal disease, or (3) death.
Gassman et al. (Tue,) conducted a rct in Hypertensive kidney disease. Ramipril, amlodipine, or metoprolol; lower BP goal (MAP ≤92 mmHg) vs usual BP goal (MAP 102-107 mmHg) vs. Active comparators and different BP goals was evaluated on Rate of change in renal function as measured by GFR, assessed by (125) I-iothalamate clearance. The AASK trial is designed to evaluate the effectiveness of three anti-hypertensive drug regimens and two levels of blood pressure control on the progression of hypertensive kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: